



**Press Release**  
December 30, 2021  
Gothenburg, Sweden

## **Change in number of shares and votes in Vitrolife AB (publ)**

In accordance with the decision at the Extraordinary General Meeting on 20 October 2021, Vitrolife AB has issued a total of 17,251,312 new shares. As of 30 December 2021, following the new issue of shares, the number of shares and votes in Vitrolife AB (publ) amounts to 135,447,190.

Gothenburg, December 30, 2021  
VITROLIFE AB (publ)  
Thomas Axelsson, CEO

**Contact persons:**

Thomas Axelsson, CEO, tel: +46 31 721 80 01  
Mikael Engblom, CFO, tel: +46 31 721 80 14

---

Vitrolife is an international medical device and genetic services Group. Vitrolife develops, produces and markets products for reproductive health together with services that provide personalised genetic information to improve clinical practices in infertility, women's health and rare diseases. Headquartered in Gothenburg, Sweden, the Group currently employs approximately 1,200 people worldwide. Its products, services and solutions are available in more than 110 markets through a network of subsidiaries and distributors. The Group has a wide-ranging experience in the fertility field with an advanced research capacity. The Vitrolife share is listed on NASDAQ Stockholm.

---

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com).  
Website: [www.vitrolife.com](http://www.vitrolife.com)

This information is such that Vitrolife AB (publ) is obliged to publish according to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 5.30 pm CET on December 30, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.